AUTL:NSD-Autolus Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.57

Change

0.00 (0.00)%

Market Cap

USD 0.53B

Volume

2.09M

Average Target Price

USD 14.83 (+95.95%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

Company Website : http://www.autolus.com

Address : Forest House, London, United Kingdom, W12 7RZ

Employees : 376

Fiscal Year End : September

Currency: USD

Country : USA

Technical Indicators

Beta : 1.69

52 Week High : 17.19

Short Ratio : 1.22

52 Week Low : 4.60

Shorted Shares : 2,232,305

200 Day Moving Average : 7.18

Shorted Shares Previous Month : 2,322,149

50 Day Moving Average : 6.39

Shares Held By Insiders : 25.58%

Short Percentage : 3.00%

Shares Held by Institutions : 31.8%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD79.98B 133.51 104.16
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD57.31B 15.31 11.96
BNTX BioNTech SE

N/A

 USD51.30B -99,999.99 31.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD48.63B 17.91 12.34
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.06B 58.65 41.96
BGNE BeiGene, Ltd

N/A

 USD29.61B N/A N/A
SGEN Seagen Inc

N/A

 USD28.37B 43.61 39.21
GMAB Genmab A/S

N/A

 USD28.05B 26.59 3.73
RPRX Royalty Pharma plc

N/A

 USD26.73B 22.60 15.75
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD20.79B N/A N/A

ETFs Containing AUTL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.32% 32% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.32% 32% F 16% F
Trailing 12 Months  
Capital Gain -44.17% 16% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.17% 16% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -23.15% 9% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.15% 9% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 30.12% 86% B 59% F
Risk Adjusted Return -76.86% 7% F 2% F
Market Capitalization 0.53B 57% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.74 87% B+ 69% D+
Price / Cash Flow Ratio -4.53 32% F 66% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -29.62% 76% C 31% F
Return on Invested Capital -61.94% 38% F 13% F
Return on Assets -22.28% 54% F 16% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.22 82% B- 74% C
Short Percent 6.58% 51% F 30% F
Beta 1.69 32% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector